Compounds for enzyme inhibition
View Patent ↗Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
1. A method for treating a hematopoietic cancer, which comprises administering to a subject in need thereof an effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the hematopoietic cancer is leukemia.
3. The method of claim 2 , wherein the leukemia is acute lymphocytic leukemia.
4. The method of claim 2 , wherein the leukemia is acute myelocytic leukemia.
5. The method of claim 4 , wherein the acute myelocytic leukemia is acute promyelocytic leukemia.
6. The method of claim 2 , wherein the leukemia is adult T-cell leukemia.
7. The method of claim 2 , wherein the leukemia is chronic lymphocytic leukemia.
8. The method of claim 2 , wherein the leukemia is chronic myelocytic leukemia.
9. The method of claim 1 , wherein the hematopoietic cancer is lymphoma.
10. The method of claim 9 , wherein the lymphoma is Burkitt's lymphoma.
11. The method of claim 9 , wherein the lymphoma is histiocytic lymphoma.
12. The method of claim 1 , wherein compound or pharmaceutically acceptable salt thereof is administered by intravenous administration.
13. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is in the form of a composition comprising the compound or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
14. The method of claim 13 , wherein each of the one or more pharmaceutically acceptable carriers is independently selected from a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent, a coating agent, a cyclodextrin, and a buffer.
15. The method of claim 13 , wherein each of the one or more pharmaceutically acceptable carriers is independently selected from:
(1) a sugar selected from lactose, glucose, and sucrose; (2) a starch selected from corn starch, potato starch, and substituted or unsubstituted β-cyclodextrin; (3) cellulose or a derivative selected from sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) an excipient selected from cocoa butter and suppository waxes; (9) an oil selected from peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) propylene glycol; (11) a polyol selected from glycerin, sorbitol, mannitol, and polyethylene glycol; (12) an ester selected from ethyl oleate and ethyl laurate; (13) agar; (14) a buffering agent selected from magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
16. The method of claim 13 , wherein at least one of the one or more pharmaceutically acceptable carriers is a cyclodextrin.
17. The method of claim 13 , wherein at least one of the one or more pharmaceutically acceptable carriers is a substituted or unsubstituted β-cyclodextrin.
18. The method of claim 13 , wherein at least one of the one or more pharmaceutically acceptable carriers is a buffer.
19. The method of claim 13 , wherein the composition further comprises an anti-oxidant.
20. The method of claim 19 , wherein the anti-oxidant is citric acid.
21. The method of claim 13 , wherein the composition further comprises one or more other therapeutic agents.
22. The method of claim 21 , wherein at least one of the one or more other therapeutic agents is a chemotherapeutic agent.
23. The method of claim 13 , wherein the composition is in a solid form that is suitable for reconstitution in a sterile injectable medium.
24. The method of claim 13 , wherein the composition further comprises water.
25. The method of claim 24 , wherein the water is sterile water.
26. The method of claim 25 , wherein the composition is in the form of an aqueous solution, dispersion, suspension or emulsion.
27. The method of claim 13 , wherein the composition is administered by intravenous administration.